Interv Akut Kardiol. 2009;8(6):322-324

Beta blockers in the treatment of acute heart failure

Tomáš Janota
III. interní klinika VFN a 1. LF UK, Praha

Beta blockers boast a number of advantageous effects. Substantial is a deceleration of heart rate, leading to the decrease in metabolic

demands of the myocardium, improvement of left ventricle filling, as well as improvement in the subendocardial blood flow. They

also decrease arterial blood pressure, have antiarrhythmic effects and in long term use in chronic heart failure lead to an increase in

left ventricle ejection fraction. Beta blockers can also improve myocardial function in acute heart failure. It is nowadays a standard

practice to continue chronic beta blocker medication in acute exacerbation of chronic heart failure when possible. In newly manifested

more severe heart failure or in those not yet started on beta blocker therapy, its initiation can lead to major improvement especially

in those with significant tachycardia. Short-acting or very short-acting drugs are recommended for the initiation, as well as the whole

duration of treatment in acute heart failure, allowing for safe trial of efficacy and tolerance. It is important to use only high selective

beta-1-blockers. The positive effect of beta blockers initiated after the acute phase of heart failure has been documented in large trials,

however, there is increasing evidence from case studies and experimental work that initiation of beta blockers during the acute phase

of heart failure has benefits, too.

Keywords: acute heart failure, treatment, beta blockers

Published: December 12, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Janota T. Beta blockers in the treatment of acute heart failure. Interv Akut Kardiol. 2009;8(6):322-324.
Download citation

References

  1. Kjekshus JK. Importance of heart rate in determining betablocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 1986; 57: 43F-49F. Go to original source... Go to PubMed...
  2. Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol. 2001; 37: 1950-1956. Go to original source... Go to PubMed...
  3. Mooss AN, Hilleman DE, Mohiuddin SM, Hunter CB. Safety of esmolol in patients with acute myocardial infarction treated with thrmobolytic therapy who had relative contraindications to beta-blocker therapy. An Phar 1994: 28: 701-703. Go to original source... Go to PubMed...
  4. Borchard U. Klinische Pharmakologie der ?-Rezeptorenblocker. Basel. Aesopus-Verlag, 1996.
  5. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13. Go to original source...
  6. MERIT-HF Sudy Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007. Go to original source...
  7. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N England J Med 2001; 344: 1651-1658. Go to original source... Go to PubMed...
  8. Špinar J, Hradec J, Málek I, Toman J. Doporučení pro léčbu a diagnostiku srdečního selhání. Cor Vasa 2001; 43: K123-137.
  9. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJV, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J. 2008; doi: 10.1093/eurheartj/ehn309. Go to original source... Go to PubMed...
  10. Špinar J, Janský P, Kettner J, Málek I. Doporučení pro diagnostiku a léčbu akutního srdečního selhání. Cor Vasa 2006; 48: K3-K31.
  11. Second Chinese Cardiac Study (CCS-2) Collaborative Group. Rationale, design and organization of the Second Chinese Cardiac Study (CCS-2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. J Cardiovasc Risk 2000; 7: 435-441. Go to original source...
  12. Herlitz J, Elmfeldt D, Hjalmarson A, et al. Effect of metoprolol on indirect signs of the size and severity of acute myocardial infarction. Am J Cardiol 1983; 51: 1282-1288. Go to original source... Go to PubMed...
  13. Herlitz J, Waagstein F, Lindqvist J, et al. Effect of metoprolol on the prognosis for patients with suspected acute myocardial infarction and indirect signs of congestive heart failure (a subgroup analysis of the Goteborg Metoprolol Trial). Am J Cardiol 1997; 80: 40J-44J. Go to original source... Go to PubMed...
  14. Špinar J, Hradec J, Meluzín J, et al. Doporučení pro diagnostiku a léčbu chronického srdečního selhání ČKS 2006. Cor Vasa 2007; 49: K5-K34.
  15. Dickstein K, Cohen-Solal A, Filippatos G, et al. Acute and Chronic Heart Failure (Diagnosis and Treatment). Eur Heart J 2008: 29; 2388-2442. Go to original source...
  16. Izumi Y, Okatani H, Shiota M, et al. Effects of metoprolol on epinephrine-induced takotsubo-like left ventricular dysfunction in non-human primates. Hypertens Res 2009; 32: 339-346. Go to original source... Go to PubMed...
  17. Raby KE, Brull SJ, Timimi F, et al. The Effect of Heart Rate Control on Myocardial Ischemia among High-Risc Patients After Vascular Surgery. Anest Analg 1999; 88: 477-482. Go to original source...
  18. Urban, et al. Postoperative Prophylactic Administration of ?-Adrenergic Blockers in Patients at Risk for Myocardial Ischemia. Anest Analg. 2000. Go to original source...
  19. Kirshenbaum, et al. Use of an Ultrashort-Acting beta-Receptor Blocker (Esmolol) in Patients With Acute Myocardial Ischemia and Relative Contraindications to Beta-Blockade Therapy. JACC 1988; 773-780. Go to original source... Go to PubMed...
  20. Held PH, Corbeij HM, Dunselman P, et al. Hemodynamic effects of metoprolol in acute myocardial infarction. A randomized, placebo controlled multicenter study. Am J Cardiol 1985; 56: 47G-54G. Go to original source... Go to PubMed...
  21. Janota T, Malík J, Hradec J. Zkušenosti s podáním ultrakrátce působícího beta-blokátoru esmololu u nemocných s kontraindikací betablokátorů. Interv Akut Kardiol 2004; 2: 28-30.
  22. Mooss AN, Hilleman DE, Mohiuddin SM, Hunter CB. Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy. Ann Pharmacother 1994; 28: 701-703. Go to original source... Go to PubMed...




Interventional Cardiology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.